Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 9/20 | 0.68 |
| ▸ | KDR | P35968 | 4/20 | 0.68 |
| ▸ | LCK | P06239 | 3/20 | 0.68 |
| ▸ | JAK2 | O60674 | 2/20 | 0.68 |
| ▸ | FYN | P06241 | 2/20 | 0.68 |
| ▸ | SRC | P12931 | 2/20 | 0.68 |
| ▸ | FER | P16591 | 2/20 | 0.68 |
| ▸ | BLK | P51451 | 2/20 | 0.68 |
| ▸ | CDC7 | O00311 | 1/20 | 0.68 |
| ▸ | PLK4 | O00444 | 1/20 | 0.68 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.68 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.68 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.68 |
| ▸ | INSR | P06213 | 1/20 | 0.68 |
| ▸ | CDK1 | P06493 | 1/20 | 0.68 |
| ▸ | ROS1 | P08922 | 1/20 | 0.68 |
| ▸ | PRKACA | P17612 | 1/20 | 0.68 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.68 |
| ▸ | CDK2 | P24941 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28423335 | 1.00 | RET (0.68) | RETKDRLCKJAK2FYN | |
| SCHEMBL16594430 | 1.00 | RET (0.68) | RETKDRLCKJAK2FYN | |
| SCHEMBL17911520 | 0.93 | RET (0.62) | RETKDRLCKJAK2FYN | |
| SCHEMBL17911522 | 0.93 | RET (0.62) | RETKDRLCKJAK2FYN | |
| Bicarbonate SCHEMBL27088025 | 0.89 | RET (0.80) | RETKDRLCKJAK2FYN | |
| SCHEMBL17235726 | 0.87 | BTK (0.63) | RETKDRLCKJAK2FYN | |
| SCHEMBL17267632 | 0.87 | BTK (0.63) | RETKDRLCKJAK2FYN | |
| SCHEMBL17267631 | 0.87 | BTK (0.63) | RETKDRLCKJAK2FYN | |
| SCHEMBL21292635 | 0.86 | JAK3 (0.60) | RETKDRLCKJAK2FYN | |
| SCHEMBL21292738 | 0.86 | JAK3 (0.60) | RETKDRLCKJAK2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138842-B1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | ZHEJIANG DTRM BIOPHARMA CO LTD (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-10300066-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20180207161-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-9861636-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2018-01-09 | — | — | US | disclosed |
| EP-2947086-B1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-20170065594-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3138842-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
| US-9532990-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-01-03 | — | — | US | disclosed |
| US-20160200730-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2016-07-14 | — | — | US | disclosed |
| EP-2947086-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2015-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200730-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | BTK, LCK, LYN | RET 259/4885KDR 674/4885LCK 2/4885 |
| US-20170065594-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | BTK, LCK, LYN | RET 259/4885KDR 674/4885LCK 2/4885 |
| US-20180207161-A1 | POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS | BTK, LCK, LYN | RET 259/4885KDR 674/4885LCK 2/4885 |
| US-10300066-B2 | Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors | BTK, LCK, LYN | RET 259/4885KDR 674/4885LCK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.